Biologicals and Fetal Cell Therapy for Wound and Scar Management
Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Vari...
Gespeichert in:
| Veröffentlicht in: | ISRN Dermatology 2011-01, Vol.2011 (2011), p.1-16 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 2011 |
| container_start_page | 1 |
| container_title | ISRN Dermatology |
| container_volume | 2011 |
| creator | Hirt-Burri, Nathalie Ramelet, Albert-Adrien Raffoul, Wassim de Buys Roessingh, Anthony Scaletta, Corinne Pioletti, Dominique Laurent-Applegate, L. A. |
| description | Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management. |
| doi_str_mv | 10.5402/2011/549870 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3262533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2592689661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3090-c07684c1a46e387990dffe5275459e8359264ece312a7e3f3e2d065aa256a2c63</originalsourceid><addsrcrecordid>eNqFkc1LxDAQxYMoKqsnz0rxIiir6aRJ2ouoi1-w4kHFYxjT6W6l26zpVvG_N0vdRb2YywTmN2_e8BjbifmxTDicAI_jE5lkqeYrbBN4xvuJ4mp18ZcZbLDtpnnl4UkOUqt1tgEglEil2GRnF6Wr3Ki0WDUR1nl0RTOsogFVVfQ4Jo_Tz6hwPnp2bWjOgQeLPrrDGkc0oXq2xdaKMEvb37XHnq4uHwc3_eH99e3gfNi3Ym7Ecq3SxMaYKBKpzjKeFwVJ0DJYpFQEnyohSyIG1CQKQZBzJRFBKgSrRI-ddrrT9mVCuQ2rPVZm6ssJ-k_jsDS_O3U5NiP3bgQokEIEgYNvAe_eWmpmZlI2NtyJNbm2MRkIqaXIskDu_yFfXevrcF2AQCupJAToqIOsd03jqVhaibmZR2Pm0ZgumkDv_XS_ZBdBBOCwA8ZlneNH-Y_abgdTQKjAJZykXEMivgBdRZ0q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>922765652</pqid></control><display><type>article</type><title>Biologicals and Fetal Cell Therapy for Wound and Scar Management</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Hirt-Burri, Nathalie ; Ramelet, Albert-Adrien ; Raffoul, Wassim ; de Buys Roessingh, Anthony ; Scaletta, Corinne ; Pioletti, Dominique ; Laurent-Applegate, L. A.</creator><contributor>Gesser, B. ; Messadi, D. V. ; Zalewska, A. ; Amichai, B. ; Pasmatzi, E.</contributor><creatorcontrib>Hirt-Burri, Nathalie ; Ramelet, Albert-Adrien ; Raffoul, Wassim ; de Buys Roessingh, Anthony ; Scaletta, Corinne ; Pioletti, Dominique ; Laurent-Applegate, L. A. ; Gesser, B. ; Messadi, D. V. ; Zalewska, A. ; Amichai, B. ; Pasmatzi, E.</creatorcontrib><description>Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management.</description><identifier>ISSN: 2090-4592</identifier><identifier>EISSN: 2090-4606</identifier><identifier>DOI: 10.5402/2011/549870</identifier><identifier>PMID: 22363853</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Advantages ; Biological products ; Blood & organ donations ; Cell division ; Good Manufacturing Practice ; Medical technology ; Pediatrics ; R&D ; Research & development ; Review ; Skin ; Stem cells ; Transplants & implants ; Wound healing</subject><ispartof>ISRN Dermatology, 2011-01, Vol.2011 (2011), p.1-16</ispartof><rights>Copyright © 2011 Nathalie Hirt-Burri et al.</rights><rights>Copyright © 2011 Nathalie Hirt-Burri et al. Nathalie Hirt-Burri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2011 Nathalie Hirt-Burri et al. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3090-c07684c1a46e387990dffe5275459e8359264ece312a7e3f3e2d065aa256a2c63</citedby><cites>FETCH-LOGICAL-c3090-c07684c1a46e387990dffe5275459e8359264ece312a7e3f3e2d065aa256a2c63</cites><orcidid>0000-0002-3524-0077</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262533/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262533/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22363853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Gesser, B.</contributor><contributor>Messadi, D. V.</contributor><contributor>Zalewska, A.</contributor><contributor>Amichai, B.</contributor><contributor>Pasmatzi, E.</contributor><creatorcontrib>Hirt-Burri, Nathalie</creatorcontrib><creatorcontrib>Ramelet, Albert-Adrien</creatorcontrib><creatorcontrib>Raffoul, Wassim</creatorcontrib><creatorcontrib>de Buys Roessingh, Anthony</creatorcontrib><creatorcontrib>Scaletta, Corinne</creatorcontrib><creatorcontrib>Pioletti, Dominique</creatorcontrib><creatorcontrib>Laurent-Applegate, L. A.</creatorcontrib><title>Biologicals and Fetal Cell Therapy for Wound and Scar Management</title><title>ISRN Dermatology</title><addtitle>ISRN Dermatol</addtitle><description>Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management.</description><subject>Advantages</subject><subject>Biological products</subject><subject>Blood & organ donations</subject><subject>Cell division</subject><subject>Good Manufacturing Practice</subject><subject>Medical technology</subject><subject>Pediatrics</subject><subject>R&D</subject><subject>Research & development</subject><subject>Review</subject><subject>Skin</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><subject>Wound healing</subject><issn>2090-4592</issn><issn>2090-4606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkc1LxDAQxYMoKqsnz0rxIiir6aRJ2ouoi1-w4kHFYxjT6W6l26zpVvG_N0vdRb2YywTmN2_e8BjbifmxTDicAI_jE5lkqeYrbBN4xvuJ4mp18ZcZbLDtpnnl4UkOUqt1tgEglEil2GRnF6Wr3Ki0WDUR1nl0RTOsogFVVfQ4Jo_Tz6hwPnp2bWjOgQeLPrrDGkc0oXq2xdaKMEvb37XHnq4uHwc3_eH99e3gfNi3Ym7Ecq3SxMaYKBKpzjKeFwVJ0DJYpFQEnyohSyIG1CQKQZBzJRFBKgSrRI-ddrrT9mVCuQ2rPVZm6ssJ-k_jsDS_O3U5NiP3bgQokEIEgYNvAe_eWmpmZlI2NtyJNbm2MRkIqaXIskDu_yFfXevrcF2AQCupJAToqIOsd03jqVhaibmZR2Pm0ZgumkDv_XS_ZBdBBOCwA8ZlneNH-Y_abgdTQKjAJZykXEMivgBdRZ0q</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Hirt-Burri, Nathalie</creator><creator>Ramelet, Albert-Adrien</creator><creator>Raffoul, Wassim</creator><creator>de Buys Roessingh, Anthony</creator><creator>Scaletta, Corinne</creator><creator>Pioletti, Dominique</creator><creator>Laurent-Applegate, L. A.</creator><general>Hindawi Puplishing Corporation</general><general>International Scholarly Research Network</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3524-0077</orcidid></search><sort><creationdate>20110101</creationdate><title>Biologicals and Fetal Cell Therapy for Wound and Scar Management</title><author>Hirt-Burri, Nathalie ; Ramelet, Albert-Adrien ; Raffoul, Wassim ; de Buys Roessingh, Anthony ; Scaletta, Corinne ; Pioletti, Dominique ; Laurent-Applegate, L. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3090-c07684c1a46e387990dffe5275459e8359264ece312a7e3f3e2d065aa256a2c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Advantages</topic><topic>Biological products</topic><topic>Blood & organ donations</topic><topic>Cell division</topic><topic>Good Manufacturing Practice</topic><topic>Medical technology</topic><topic>Pediatrics</topic><topic>R&D</topic><topic>Research & development</topic><topic>Review</topic><topic>Skin</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirt-Burri, Nathalie</creatorcontrib><creatorcontrib>Ramelet, Albert-Adrien</creatorcontrib><creatorcontrib>Raffoul, Wassim</creatorcontrib><creatorcontrib>de Buys Roessingh, Anthony</creatorcontrib><creatorcontrib>Scaletta, Corinne</creatorcontrib><creatorcontrib>Pioletti, Dominique</creatorcontrib><creatorcontrib>Laurent-Applegate, L. A.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ISRN Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirt-Burri, Nathalie</au><au>Ramelet, Albert-Adrien</au><au>Raffoul, Wassim</au><au>de Buys Roessingh, Anthony</au><au>Scaletta, Corinne</au><au>Pioletti, Dominique</au><au>Laurent-Applegate, L. A.</au><au>Gesser, B.</au><au>Messadi, D. V.</au><au>Zalewska, A.</au><au>Amichai, B.</au><au>Pasmatzi, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biologicals and Fetal Cell Therapy for Wound and Scar Management</atitle><jtitle>ISRN Dermatology</jtitle><addtitle>ISRN Dermatol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>2011</volume><issue>2011</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><issn>2090-4592</issn><eissn>2090-4606</eissn><abstract>Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta, and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of outscaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors, and development. Safety has been evidenced in Phase I and II clinical fetal cell use for burn and wound treatments with different cell delivery systems. We present herein that fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>22363853</pmid><doi>10.5402/2011/549870</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-3524-0077</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2090-4592 |
| ispartof | ISRN Dermatology, 2011-01, Vol.2011 (2011), p.1-16 |
| issn | 2090-4592 2090-4606 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3262533 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Advantages Biological products Blood & organ donations Cell division Good Manufacturing Practice Medical technology Pediatrics R&D Research & development Review Skin Stem cells Transplants & implants Wound healing |
| title | Biologicals and Fetal Cell Therapy for Wound and Scar Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A56%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biologicals%20and%20Fetal%20Cell%20Therapy%20for%20Wound%20and%20Scar%20Management&rft.jtitle=ISRN%20Dermatology&rft.au=Hirt-Burri,%20Nathalie&rft.date=2011-01-01&rft.volume=2011&rft.issue=2011&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.issn=2090-4592&rft.eissn=2090-4606&rft_id=info:doi/10.5402/2011/549870&rft_dat=%3Cproquest_pubme%3E2592689661%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=922765652&rft_id=info:pmid/22363853&rfr_iscdi=true |